12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

NCT ID: NCT00664859

Last Updated: 2020-03-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 140 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-10-31
• Study Completion Date: 2009-02-28

Brief Summary

The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia

Detailed Description

POPULATION:

Subjects with mixed dyslipidemia (non-HDL cholesterol > 130 mg/dL and TG ≥ 150 mg/dL and ≤ 500 mg/dL) who completed the double-blind study (LCP-AtorFen-2001; NCT00504829), met the enrollment criteria (all of the inclusion criteria and none of the exclusion criteria), and elected to enter the open-label extension study.

STUDY DESIGN AND DURATION:

This is a 52-week, open-label, single-treatment arm with 8 visits (Weeks 0, 4, 8, 12, 24, 36, 48 and 52). A maximum of approximately 200 subjects will enter this open-label safety and efficacy extension study from the LCP AtorFen-2001 double-blind study. All subjects enrolled in this study will receive open-label LCP-AtorFen combination therapy. Visit 1 of the extension study corresponds to the last visit of the double-blind study (Visit 6 or Week 12).

Conditions

Dyslipidemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single

Open-label LCP-AtorFen

Group Type: EXPERIMENTAL

LCP-AtorFen

Intervention Type: DRUG

All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.

Interventions

LCP-AtorFen

All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.

Intervention Type: DRUG

Other Intervention Names

atorvastatin and fenofibrate combination therapy

Eligibility Criteria

Inclusion Criteria

1. Subject has successfully completed the double-blind study (LCP-AtorFen-2001; NCT00504829).

2. Subject has confirmed his or her willingness to participate in this study after being informed of all aspects of the study by voluntarily signing and dating an informed consent form in accordance with Good Clinical Practice (GCP).

Exclusion Criteria

1. Study drug compliance <70% in the double-blind study.

2. Any ongoing serious adverse event, or any ongoing non-serious moderate or severe adverse event from the double-blind study that is rated as possibly, probably or definitely related to study drug.

3. Resting blood pressure >/=160 mm Hg systolic and/or >/=100 mm Hg diastolic.

4. Symptoms of unexplained muscle pain, tenderness or weakness (i.e., signs indicative of possible myopathy), or any diagnosis of myopathy or rhabdomyolysis.

5. Any clinically significant change in physical exam or electrocardiogram from Visit 2 to Visit 6 of the double-blind study.

6. Any clinically significant change from Visit 1 to Visit 6 of the double-blind study in medical history including, but not limited to: a diagnosis of insulin-dependent diabetes mellitus (DM); poorly controlled DM; poorly controlled hypertension; significant renal, pulmonary, hepatic, biliary, or gastrointestinal disease; cancer (except non-melanoma skin cancer); and epilepsy.

7. Unwilling to abstain from medications, supplements, ingredients and herbal therapies that were excluded in the double-blind study and continue to be excluded in the open-label study.

8. Women who are pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential (not surgically sterilized between menarche and menopause) who are not using a medically approved method of contraception.

9. Other exclusion conditions might apply.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Veloxis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jeff Geohas, MD

Role: PRINCIPAL_INVESTIGATOR

Radiant Research

Dennis McCluskey, MD

Role: STUDY_DIRECTOR

Radiant Resaerch

Harry Geisberg, MD

Role: STUDY_DIRECTOR

Radiant Research

Chivers Woodruff, Jr, MD

Role: STUDY_DIRECTOR

Radiant Research

Michael Noss, MD

Role: STUDY_DIRECTOR

Radiant Research

Michele Reynolds, MD

Role: STUDY_DIRECTOR

Radiant Research

James Zavoral, MD

Role: STUDY_DIRECTOR

Radiant Research

Randall Severance, MD

Role: STUDY_DIRECTOR

Radiant Research

Stephen Halpern, MD

Role: STUDY_DIRECTOR

Radiant Research

Linda Murray, MD

Role: STUDY_DIRECTOR

Radiant Research

Eduardo Cuevas, MD

Role: STUDY_DIRECTOR

Radiant Research

Cynthia Strout, MD

Role: STUDY_DIRECTOR

Coastal Carolina Research

Mark Kipnes, MD

Role: STUDY_DIRECTOR

Diabetes and Glandular Research Center, Inc.

Locations

Radiant Research, 515 N State St, Suite 2700

Chicago, Illinois, United States

Countries

United States

Other Identifiers

LCP-AtorFen-2001-1X

Identifier Type: -

Identifier Source: org_study_id